![Erlich Yaniv](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Erlich Yaniv is the founder of Eleven Therapeutics Ltd.
He held the titles of Chief Executive & Scientific Officer at the company.
His job functions included CEO, CTO, and FOU.
He is no longer active in this role.
Aktive Positionen von Erlich Yaniv
Unternehmen | Position | Beginn |
---|---|---|
Eleven Therapeutics Ltd.
![]() Eleven Therapeutics Ltd. Medical/Nursing ServicesHealth Services Eleven Therapeutics Ltd. is an Israeli biotech company that combines artificial intelligence, functional assays, and combinatorial chemistry to develop RNAi therapeutics. The company was founded in 2020 by a group of interdisciplinary scientists and has three collaborative hubs located in undisclosed locations. The company is based in an undisclosed location. Eleven Therapeutics is currently focused on developing siRNA treatments for respiratory diseases using its flagship invention, SCSI-RNA™. This fully programmable molecule is designed to address the delivery, durability, and efficacy challenges of any disease and biological target of interest. The company was founded by Erlich Yaniv, Shaun Ilan, Greg Hannon, and Erlich Yaniv has been the CEO since incorporation. | Vorstandsvorsitzender | 01.01.2017 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Eleven Therapeutics Ltd.
![]() Eleven Therapeutics Ltd. Medical/Nursing ServicesHealth Services Eleven Therapeutics Ltd. is an Israeli biotech company that combines artificial intelligence, functional assays, and combinatorial chemistry to develop RNAi therapeutics. The company was founded in 2020 by a group of interdisciplinary scientists and has three collaborative hubs located in undisclosed locations. The company is based in an undisclosed location. Eleven Therapeutics is currently focused on developing siRNA treatments for respiratory diseases using its flagship invention, SCSI-RNA™. This fully programmable molecule is designed to address the delivery, durability, and efficacy challenges of any disease and biological target of interest. The company was founded by Erlich Yaniv, Shaun Ilan, Greg Hannon, and Erlich Yaniv has been the CEO since incorporation. | Health Services |